COVID19

Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials

June, 2022

Abstract

Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest observed in phase III randomized trials of mRNA COVID-19 vaccines.

A Final Report Card on the States’ Response to COVID-19

April, 2022

Abstract

Almost exactly two years ago COVID-19 spread to the United States. Following the federalism model, the 50 states and their governors and legislators made many of their own pandemic policy choices to mitigate the damage from the virus. States learned from one another over time about what policies worked most and least effectively in terms of containing the virus while minimizing the negative effects of lockdown strategies on businesses and children.

C19 Vax Strategy: Geert Vanden Bossche and Robert Malone, MD

Citation impact and social media visibility of Great Barrington and John Snow signatories for COVID-19 strategy

January, 2022

Abstract

Objective 

The Great Barrington Declaration (GBD) and the John Snow Memorandum (JSM), each signed by numerous scientists, have proposed hotly debated strategies for handling the COVID-19 pandemic. The current analysis aimed to examine whether the prevailing narrative that GBD is a minority view among experts is true.

Methods 

Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs

January, 2022

Highlights

• mRNA vaccines promote sustained synthesis of the SARS-CoV-2 spike protein.

• The spike protein is neurotoxic, and it impairs DNA repair mechanisms.

• Suppression of type I interferon responses results in impaired innate immunity.

• The mRNA vaccines potentially cause increased risk to infectious diseases and cancer.

• Codon optimization results in G-rich mRNA that has unpredictable complex effects.

Abstract

Pages